This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The primary health outcomes used were the number of chronic HBV carriers, caused by perinatal transmission, prevented. Life years saved were also estimated.
Effectiveness results
The routine screening programme would result in an annual 2.6 neonatal carriers prevented and an annual 3.1 childhood carriers prevented. Assuming a normal life span of 72 years, this represents a gain of 6.7 life years per carrier.
Clinical conclusions
Current practice identified 7 surface-antigen positive mothers in 26,500 pregnancies per year, whereas 22 were expected. Routinescreening should prevent 0.8 deaths per year later in life at a median age of 45 and would result in the saving of 21 life years.
Modelling
A decision tree was used to model effectiveness outcomes.
Measure of benefits used in the economic analysis
Childhood carriers prevented and life-years saved.
Direct costs
Some costs and quantities were reported separately. The costs involved in the envisaged programme fell into 2 categories:
(1) the costs involved in the screening (the extra testing involved) and
(2) responding to a positive screening test, further costs involved confirmatory tests, tests to establish HBeAG status and anti-HBe status and the costs involved in treating the children of women who were anti-HBe negative (a course of 3 doses of vaccine and HBIg).
Costs were considered from the point of view of the Health Service provider. Costs were calculated for screening test kits, increased overheads involved in the greater number of tests, confirmatory tests, 3 dose of vaccine and HBIg. The costs of testing kits were estimated by the Regional Blood Transfusion Service. A separate estimate of the costs of testswas provided by the Cambridge Public Health Laboratory at Addenbrooke's Hospital. Costs were not discounted.
Currency

UK pounds Sterling ().
Sensitivity analysis
To test final cost-effectiveness, sensitivity analyses were carried out on the following parameters: cost of test kits, both higher and lower maternal HBsAg prevalence, the percentage of maternal HBsAg carriers positive for HBeAG uptake or compliance, sensitivity and specificity of laboratory tests for HBsAg test,
